Optimizing patient selection for secondary cytoreductive surgery in recurrent endometrial cancer

被引:0
|
作者
Vargiu, Virginia [1 ]
Rosati, Andrea [1 ,2 ]
Tortorella, Lucia [1 ]
Giannarelli, Diana [3 ]
Capozzi, Vito Andrea [4 ]
Gallotta, Valerio [1 ]
Gioe, Alessandro [1 ]
Di Stefano, Ettore [2 ]
Corrado, Martina [2 ]
Berretta, Roberto [4 ]
Cosentino, Francesco [5 ]
Scambia, Giovanni [1 ,2 ]
Fanfani, Francesco [1 ,2 ]
机构
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Facil Epidemiol & Biostat, Rome, Italy
[4] Univ Parma, Dept Med & Surg, Parma, Italy
[5] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy
关键词
Endometrial Neoplasms; Neoplasm Recurrence; Local; Cytoreduction surgical procedures; SURGICAL-MANAGEMENT;
D O I
10.1136/ijgc-2024-005383
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective This retrospective, multicenter, observational study aimed to refine patient selection criteria for secondary cytoreductive surgery in recurrent endometrial cancer. The objective was to identify preoperative predictors of complete cytoreduction, assess surgical complexity, and propose a preoperative predictive scoring system to identify suitable candidates for secondary cytoreductive surgery. Methods Data from 331 women with recurrent endometrial cancer were analyzed across three Italian centers from January 2010 to December 2021. Patients were categorized based on treatment received (medical treatment, diagnostic laparoscopy/examination under anesthesia, or secondary cytoreductive surgery). Preoperative predictors, surgical complexity, complications, and a predictive scoring system were assessed. Logistic regression and receiver operating characteristic analysis were used for statistical evaluation. Results Of the cohort, 56.2% underwent debulking surgery, 17.2% had diagnostic laparoscopy, and 26.6% received medical treatment. Patients undergoing secondary cytoreductive surgery were younger, with a lower body mass index, better performance status, and fewer comorbidities. Single site locoregional relapse was common in secondary cytoreductive surgery patients. Age <65 years, single site relapse, lymph node, and hematogenous relapse were independent predictors of complete cytoreduction. A predictive scoring system demonstrated a clear relationship between the score and the likelihood of complete cytoreduction. Conclusion This study identified age <65 years, single site recurrence, as well as nodal and hematogenous recurrence, as predictive factors for achieving optimal cytoreduction. A predictive scoring system incorporating these factors has been proposed to identify optimal candidates for secondary cytoreductive surgery in recurrent endometrial cancer. The scoring system showed promising predictive accuracy and could aid in refining the decision making process, ensuring appropriate patient selection for secondary cytoreductive surgery. Further prospective studies are warranted to validate and enhance the predictive model.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study
    Ren, Yulan
    Shan, Boer
    Shi, Daren
    Wang, Huaying
    BMC CANCER, 2014, 14
  • [22] Salvage cytoreductive surgery for patients with recurrent endometrial cancer: a retrospective study
    Yulan Ren
    Boer Shan
    Daren Shi
    Huaying Wang
    BMC Cancer, 14
  • [23] Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis
    Barlin, Joyce N.
    Puri, Isha
    Bristow, Robert E.
    GYNECOLOGIC ONCOLOGY, 2010, 118 (01) : 14 - 18
  • [24] Cytoreductive surgery in recurrent endometrial cancer: A new paradigm for surgical management?
    Dhanis, Joelle
    Blake, Dominic
    Rundle, Stuart
    Pijnenborg, Johanna M. A.
    Smits, Anke
    SURGICAL ONCOLOGY-OXFORD, 2022, 43
  • [25] Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis
    Barlin, J.
    Puri, I.
    Bristow, R.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S70 - S70
  • [26] The current role of secondary cytoreductive surgery for recurrent ovarian cancer
    de Bree, Eelco
    Michelakis, Dimosthenis
    Anagnostopoulou, Elisavet
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] IMPACT OF SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT EPITHELIAL OVARIAN CANCER
    Chiva de Agustin, L.
    Garcia Lavandeira, S.
    Alonso Salvador, S.
    Castellanos Alarcon, T.
    Lapuente Sastre, F.
    Gonzalez Martin, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [28] SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT EPITHELIAL OVARIAN-CANCER
    MORRIS, M
    GERSHENSON, DM
    WHARTON, JT
    COPELAND, LJ
    EDWARDS, CL
    STRINGER, CA
    GYNECOLOGIC ONCOLOGY, 1989, 34 (03) : 334 - 338
  • [29] RECURRENT OVARIAN CANCER TREATED BY SECONDARY CYTOREDUCTIVE SURGERY AND HIPEC
    Panoskaltsis, T.
    Tzavara, C.
    Pallas, N.
    Karamveri, C.
    Kiziridis, D.
    Hristakis, C.
    Kyriakopoulos, V.
    Kalakonas, A.
    Vaikos, D.
    Tentes, A-A
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A505 - A506
  • [30] Patient Selection for Cytoreductive Surgery
    Grotz, Travis E.
    Fournier, Keith F.
    Mansfield, Paul F.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 27 (03) : 443 - +